A Novel mHealth Application Guided by an Optimization Algorithm for T1D Sensor-Augmented Insulin Injection Users
I am leading a large-scale, free-living, randomized controlled study with 84 insulin injection-treated adults to test whether our learning algorithm, integrated with our mobile application, can improve blood sugar levels and treatment satisfaction over three months. Additionally, I am evaluating whether the insulin recommendations made by our algorithm are comparable to those made by a group of endocrinologists. I also plan to conduct a qualitative focus group study to explore insulin injection-user perspectives on advanced diabetes technologies.
To find out more about this study, please contact Alessandra Kobayati at: alessandra.kobayati [at] mail.mcgill.ca
ClinicalTrials.gov Identifier: NCT04123054
Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes
I am currently working on an outpatient study investigating the co-administration of insulin and pramlintide via an automated dual-hormone artificial pancreas in adults with type 1 diabetes. The goal is to develop an artificial pancreas that is safe, effective and would achieve better glycemic outcomes with minimal user input into the system.
To find out more about this study, please contact Jimmy El Maalouli at: jimmy.elmaalouli [at] mail.mcgill.ca
ClinicalTrials.gov Identifier: NCT04243629
Weekly Subcutaneous Semaglutide as Adjunct to Closed-Loop Therapy in Type 1 Diabetes Care (SEMA-AP)
I am currently running a study looking at weekly subcutaneous semaglutide while using the artificial pancreas, compared to placebo. The aim of this study is to determine if there are additional glycemic and non-glycemic benefits (such as weight loss, blood pressure control) to using the drug while on a closed-loop system.
To find out more about this study, please contact Melissa-Rosina Pasqua at: melissa-rosina.pasqua [at] mail.mcgill.ca
ClinicalTrials.gov Identifier: NCT05205928
A Trial to Compare Automated Lyumjev Delivery with Carbohydrate Counting, Qualitative Meal-Size Estimation, and Meal Detection in Type 1 Diabetes (Lilly-MEALS)
I am conducting this pilot trial to compare three meal strategies using an ultra-rapid insulin (Lyumjev) and an automated insulin delivery system. The meal strategies to be investigated are carbohydrate counting, qualitative meal announcement (e.g., low-carb meal), and meal detection. The goal is to evaluate if carbohydrate counting can be simplified in patients with type 1 diabetes.
To find out more about this study, please contact Carolyne Schumacher at: carolyne.schumacher [at] mail.mcgill.ca
ClinicalTrials.gov Identifier: NCT06021158
Effectiveness of empagliflozin added to automated insulin delivery (AID) systems in adults with type 1 diabetes with sub-optimal glycemic outcomes
I am coordinating a multi-center, placebo-controlled study, testing the effectiveness of empagliflozin use in conjunction with automated insulin delivery (AID) to improve glucose control in individuals with type 1 diabetes. The aim is to determine whether a low dose of empagliflozin daily would improve glycemic outcomes over a 26-week period.
To find out more about this study, please contact Adelyn Moore at adelyn.moore [at] mail.mcgill.ca
ClinicalTrials.gov Identifier: NCT06021145
A Fully Automated Closed-Loop Insulin and Pramlintide Delivery System for Adults with Type 1 Diabetes (FCL)
We are running a randomized, controlled, cross-over trial to assess a fully automated, dual hormone (insulin-and-pramlintide) delivery system without carbohydrate counting in regulating glucose levels in adults with type 1 diabetes. We will compare time in range between a fully automated insulin-and-pramlintide delivery system at 8μg/u and 10μg/u with a hybrid insulin-and-placebo delivery system.
To find out more about this study, please contact Joelle Doumat at joelle.doumat [at] mail.mcgill.ca.
ClinicalTrials.gov Identifier: NCT06046417